CLSA Cuts SINOPHARM TP to HKD21.1, Reiterates Outperform RatingAASTOCKS News·26 minutes ago01099+1.19%
Daiwa Cuts SINOPHARM TP to HKD17, 1H Results Slightly Miss ExpectationsAASTOCKS News·1 day ago, 09:10 PM01099+1.19%
Sinopharm FY26 1H net profit rises 2.95% to RMB 5.34 billion; revenue increases 1.13% to RMB 286.04 billionPUBT·2 days ago, 08:05 PM01099+1.19%
Sinopharm proposes re-election of Lian Wanyong, Yang Binghua as executive directorsPUBT·2 days ago, 05:22 PM01099+1.19%
Sinopharm H1 net profit drops 2.95% to RMB 5.18 billion; revenue slips 1.13% to RMB 282.8 billionPUBT·2 days ago, 05:15 PM01099+1.19%600511+0.26%
Sinopharm sells 30.13% stake in Guorui Pharma to Shanghai Shyndec for RMB 240.07 millionPUBT·Aug 19 at 09:00 AM01099+1.19%000028+0.60%
China National Medical Device, Sinopharm subsidiary, posts H1 operating profit down 12.34% to RMB 599.37 millionPUBT·Aug 19 at 03:47 AM01099+1.19%
Sinopharm files updated board and committee member list for disclosure purposesPUBT·Aug 18 at 05:34 AM01099+1.19%
Sinopharm appoints Yang Binghua to board strategy and investment committeePUBT·Aug 18 at 05:31 AM01099+1.19%
HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?Simplywall·Aug 9 at 06:31 AM02142+1.33%01099+1.19%
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?Simplywall·Jul 28 at 02:13 PM02142+1.33%01099+1.19%
HBM Holdings enters strategic biologics R&D collaboration with SinopharmPUBT·Jul 27 at 04:00 AM01099+1.19%02142+1.33%
